Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.72B | $9.32B | $9.42B | $9.21B | $8.48B | $9.79B | $9.96B | $2.55B | $2.68B | $2.76B |
| Revenue growth | — | -4.2% | 1.1% | -2.2% | -7.9% | 15.4% | 1.7% | -74.4% | 5.0% | 3.1% |
| Gross profit | $1.19B | $1.17B | $1.07B | $1.13B | $1.28B | $1.51B | $1.83B | $2.13B | $2.22B | — |
| Gross margin | 12.2% | 12.6% | 11.4% | 12.3% | 15.1% | 15.5% | 18.3% | 83.3% | 82.8% | — |
| Operating income | $200M | $89.3M | -$352M | $73.2M | $204M | $368M | $143M | $133M | -$218M | $27.5M |
| Operating margin | 2.1% | 1.0% | -3.7% | 0.8% | 2.4% | 3.8% | 1.4% | 5.2% | -8.1% | 1.0% |
| Net income | $109M | $72.8M | -$437M | -$62.4M | $29.9M | $222M | $22.4M | -$41.3M | -$363M | -$1.10B |
| Net margin | 1.1% | 0.8% | -4.6% | -0.7% | 0.4% | 2.3% | 0.2% | -1.6% | -13.5% | -39.8% |
| EPS (diluted) | $1.76 | $1.20 | -$7.28 | -$1.03 | $0.47 | $2.94 | $0.29 | -$0.53 | -$4.73 | -$14.31 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $188M | $56.8M | $116M | $166M | $339M | $124M | $325M | $741M | $161M | -$102M |
| Capital expenditures | $20.3M | $34.6M | $44.9M | $42.4M | $50.4M | $41.0M | $158M | $172M | $170M | $191M |
| Free cash flow | $167M | $22.2M | $70.7M | $124M | $289M | $83.2M | $167M | $568M | -$8.79M | -$293M |
| Share buybacks | $71.0M | $5.00M | $0.00 | — | — | — | — | — | — | $10.2M |
| Dividends paid | $63.4M | $63.2M | $48.2M | $5.23M | $648K | $731K | $0.00 | $0.00 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $185M | $105M | $66.3M | $67.0M | $83.1M | $55.7M | $69.5M | $243M | $27.6M | $282M |
| Total assets | $2.72B | $3.38B | $3.77B | $3.64B | $3.34B | $3.54B | $5.39B | $5.09B | $4.66B | $2.45B |
| Total liabilities | $1.76B | $2.36B | $3.26B | $3.18B | $2.62B | $2.60B | $4.44B | $4.17B | $4.07B | $2.91B |
| Long-term debt | $565M | $901M | $1.65B | $1.51B | $986M | — | — | — | — | — |
| Shareholders' equity | $960M | $1.02B | $518M | $462M | $712M | $939M | $967M | $945M | $586M | -$461M |
| Retained earnings | $686M | $691M | $201M | $138M | $167M | $388M | $410M | $369M | $27.2M | -$1.08B |
| Shares (wtd avg diluted) | 61.1M | 60.0M | 61.5M | 60.6M | 63.5M | 75.5M | 76.2M | 77.4M | 76.7M | 76.9M |
Every figure is extracted from ACCENDRA HEALTH INC/VA/’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.